Krystal Biotech Inc (KRYS) USD0.00001
Sell:$147.49Buy:$147.68
$2.66
(1.77%)
0.05%- This stock can be held in a
Stocks and Shares ISA$2.66
(1.77%)$2.66
(1.77%)Company Information
About this company
Krystal Biotech, Inc. is an integrated, commercial-stage biotechnology company. The Company is focused on the discovery, development, and commercialization of genetic medicines to treat diseases with high unmet medical needs. Its product candidates in various stages of clinical and preclinical development include KB407, KB408, KB707, KB105, KB801, KB803, KB304 and KB301. Its commercial product, VYJUVEK, is a redosable gene therapy, and a genetic medicine approved in the United States and Europe for the treatment of dystrophic epidermolysis bullosa. KB407 is being developed for the treatment of Cystic Fibrosis. KB408 is being developed for the treatment of Alpha-1 Antitrypsin Deficiency, a rare lung disease. KB707 is being developed for the treatment of solid tumors. KB105 is being developed for TGM1-Deficient Autosomal Recessive Congenital Ichthyosis. KB803 is a redosable eye drop formulation of B-VEC, designed for the treatment of ocular complications.
Key people
Key facts
- EPICKRYS
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- ISINUS5011471027
- Market cap$4.34bn
- Employees275
- Shares in issue28.90m
- ExchangeNASDAQ
- IndexS&P 600 Small Cap, TR Equity United States Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.